Geoffrey Kaplan
About Geoffrey Kaplan
Geoffrey Kaplan is a Regional Sales Director at Insmed Incorporated, where he has worked since 2020. He has extensive experience in pharmaceutical sales and account management, having held various roles at companies such as Novartis, Allergan, and Shire.
Current Role at Insmed
Geoffrey Kaplan serves as the Regional Sales Director at Insmed Incorporated, a position he has held since 2020. In this role, he is responsible for overseeing sales operations across multiple states, including Colorado, Utah, California, Oregon, Washington, and Hawaii. His leadership in sales strategy and execution has contributed to the company's growth in these regions.
Previous Experience at Novartis
Kaplan worked at Novartis from 2002 to 2004 as a Sales Consultant. His responsibilities included product development, training, team leadership, business development, and customer relationship management (CRM). This experience provided him with a strong foundation in the pharmaceutical industry, particularly in Arizona.
Sales Expertise and Achievements
Kaplan has extensive expertise in Medicare Part B and Part D, along with knowledge of Buy and Bill and J Codes, which are essential in pharmaceutical sales. He has a proven track record of success, having won the SOAR Award three times for top growth and being recognized as the 2022 President’s Club Winner at Insmed.
Background in Pharmaceutical Sales
Kaplan has a diverse background in pharmaceutical sales, having worked at Allergan as a Senior Sales Executive from 2005 to 2015, and at Shire as an Area Business Specialist from 2015 to 2018. His roles involved account management, strategic planning, and sales processes focused on rare and orphan diseases, enhancing his skills in the industry.
Education and Qualifications
Geoffrey Kaplan earned a Bachelor of Arts (B.A.) in Communication from the University of Arizona, completing his studies from 1998 to 2002. This educational background has supported his career in sales and business development within the pharmaceutical sector.